Extracellular Superoxide Dismutase Overexpression Can Reverse the Course of Hypoxia-Induced Pulmonary Hypertension
Hypoxia leads to free radical production, which has a pivotal role in the pathophysiology of pulmonary hypertension (PH). We hypothesized that treatment with extracellular superoxide dismutase (EC-SOD) could ameliorate the development of PH induced by hypoxia. In vitrostudies using pulmonary microvascular endothelial cells showed that cells transfected with EC-SOD had significantly less accumulation of xanthine oxidase and reactive oxygen species than nontransfected cells after hypoxia exposure for 24 h. To study the prophylactic role of EC-SOD, adult male wild-type (WT) and transgenic (TG) mice, with lung-specific overexpression of human EC-SOD (hEC-SOD), were exposed to fraction of inspired oxygen (FiO2) 10% for 10 d. After exposure, right ventricular systolic pressure (RVSP), right ventricular mass (RV/S + LV), pulmonary vascular wall thickness (PVWT) and pulmonary artery contraction/relaxation were assessed. TG mice were protected against PH compared with WT mice with significantly lower RVSP (23.9 ± 1.24 versus 47.2 ± 3.4), RV/S + LV (0.287 ± 0.015 versus 0.335 ± 0.022) and vascular remodeling, indicated by PVWT (14.324 ± 1.107 versus 18.885 ± 1.529). Functional studies using pulmonary arteries isolated from mice indicated that EC-SOD prevents hypoxia-mediated attenuation of nitric oxide-induced relaxation. Therapeutic potential was assessed by exposing WT mice to FiO2 10% for 10 d. Half of the group was transfected with plasmid containing cDNA encoding human EC-SOD. The remaining animals were transfected with empty vector. Both groups were exposed to FiO2 10% for a further 10 d. Transfected mice had significantly reduced RVSP (18.97 ± 1.12 versus 41.3 ± 1.5), RV/S + LV (0.293 ± 0.012 versus 0.372 ± 0.014) and PVWT (12.51 ± 0.72 versus 18.98 ± 1.24). On the basis of these findings, we concluded that overexpression of EC-SOD prevents the development of PH and ameliorates established PH.
This study was funded by the Department of Pediatrics at the NS-LIJ Health System.
- 14.Berrington WR. (2000) Site- and mechanismtargeted interventions for tissue free radical injury. In: Chronic Lung Disease in Early Infancy. Bland RD (ed.) Marcel Dekker Press, New York, pp. 883–909.Google Scholar
- 15.Marshall HE, Stamler JS. (2006) Nitric oxide inhibits NF-kB in the respiratory epithelium through S-nitrosylation of the P50 subunit. Am. J. Resp. Crit. Care Med. 161:A244.Google Scholar
- 17.Li FH, Xia W, Li AW, Zhao CF, Sun RP. (2007) Inhibition of rho kinase attenuates high flow induced pulmonary hypertension in rats. Chin. Med. J. (Engl). 120:22–9.Google Scholar
- 24.Reid LM. (1979) The pulmonary circulation: remodeling in growth and disease. J. Am. Rev. Respir. Dis. 119:531–46.Google Scholar
- 42.Savale L, et al. (2009) Impact of interleukin-6 on hypoxia-induced pulmonary hypertension and lung inflammation in mice. Respir. Res. 27:1–13.Google Scholar
- 43.Zhang Y, et al. (2010) Increased lung MIF expression in a hypoxia induced pulmonary hypertension mice model. Am. J. Respir. Crit. Care Med. 181:A6328.Google Scholar
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, and provide a link to the Creative Commons license. You do not have permission under this license to share adapted material derived from this article or parts of it.
The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
To view a copy of this license, visit (http://creativecommons.org/licenses/by-nc-nd/4.0/)